Titlebook: Budd-Chiari Syndrome; Xingshun Qi Book 2020 Springer Nature Singapore Pte Ltd. 2020 hepatic vein.inferior vena cava.obstruction.occlusion.

深淵

https://doi.org/10.1007/978-981-32-9232-1hepatic vein; inferior vena cava; obstruction; occlusion; thrombosis; transjugular intrahepatic portosyst

凹槽

旅行路線

,History of Budd–Chiari Syndrome,ri enriched the first description with clinical-pathological elements. Pathophysiological background of Budd–Chiari syndrome (BCS) was not known and several authors proposed different hypotheses such as syphilitic disease, endophlebitis, and trauma. The importance of an underlying condition of throm

諂媚于性

,Epidemiology of Budd–Chiari Syndrome, the literature ranges from 0.2 to 4.1 cases per million inhabitants per year, with an estimated prevalence of 2.4–7.7 per million inhabitants in Asian countries and of 1.4–4.0 per million inhabitants in Western countries. A predominance of females was reported in the West (52–69%), while in Asian s

indenture

indignant

,Imaging of Budd–Chiari Syndrome,tients without constrictive pericarditis or right heart failure. Imaging is of utmost importance in patients with BCS because it can establish the diagnosis, it helps plan further treatments, especially in case of endovascular treatment (number of abnormal vessels, aspect and length of venous stenos

發(fā)怨言

Decrepit

,Budd–Chiari Syndrome and Myeloproliferative Neoplasms,ent systemic cause. An overt MPN is diagnosed in 40% of the patients with Budd–Chiari syndrome (BCS). In BCS patients, the MPN molecular hallmark JAK2 V617F is present in up to 80% of those with overt MPN and up to 43% of those without an overt diagnosis according to the WHO criteria. In those latte

cauda-equina

Limpid